Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of “Buy” by Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been given an average rating of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $81.29.

Several equities research analysts have weighed in on GPCR shares. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. William Blair began coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock.

Structure Therapeutics Stock Up 17.4 %

GPCR stock opened at $21.76 on Friday. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $62.74. The business has a 50-day simple moving average of $20.23 and a 200 day simple moving average of $28.51. The company has a market cap of $1.25 billion, a PE ratio of -29.41 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently bought and sold shares of GPCR. ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Structure Therapeutics during the fourth quarter worth $34,000. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the fourth quarter worth $40,000. Finally, Virtus ETF Advisers LLC raised its position in Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after purchasing an additional 455 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.